Lymphoproliferative Disorder in an Esophageal Cancer Patient Treated with Pembrolizumab

被引:1
作者
Matsumura, Takashi [1 ]
Tsuchihashi, Kenji [1 ]
Yamamoto, Takeo [2 ]
Jinnouchi, Fumiaki [1 ]
Kusano, Wataru [1 ]
Kusumoto, Yota [1 ]
Arimizu, Kohei [1 ]
Ohmura, Hirofumi [3 ]
Kuma, Yuki [4 ]
Moriyama, Shohei [1 ]
Yamaguchi, Kyoko [5 ]
Ito, Mamoru [1 ]
Isobe, Taichi [3 ]
Ariyama, Hiroshi [1 ]
Oda, Yoshinao [2 ]
Akashi, Koichi [1 ]
Baba, Eishi [3 ]
机构
[1] Kyushu Univ Hosp, Dept Hematol Oncol & Cardiovasc Med, Fukuoka, Japan
[2] Kyushu Univ, Grad Sch Med Sci, Dept Anat Pathol, Kyushu, Japan
[3] Kyushu Univ, Grad Sch Med Sci, Dept Comprehens Oncol, Kyushu, Japan
[4] Kyushu Univ, Grad Sch Med Sci, Dept Dermatol, Fukuoka, Japan
[5] Kyushu Univ, Grad Sch Med Sci, Dept Med Educ, Fukuoka, Japan
关键词
Lymph proliferative disorders; EBV; Pembrolizumab; Immune checkpoint inhibitor; RHEUMATOID-ARTHRITIS; METHOTREXATE; LYMPHOMA;
D O I
10.2169/internalmedicine.3743-24
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A 75-year-old man diagnosed with esophageal cancer and lung metastasis received a combination of fluorouracil, cisplatin, and pembrolizumab. During pembrolizumab maintenance therapy, lymphoproliferative lesions at the lips and mouth and multiple lymph node swellings appeared. Histologically, Epstein-Barr virus (EBV)-encoded RNA was positive, and EBV-DNA was detected in the blood. The patient was diagnosed with other iatrogenic immunodeficiency-associated lymph proliferative disorders (OIIA-LPDs) related to EBV activation induced by pembrolizumab. Rituximab was administered, resulting in the improvement of the OIIA-LPD. The emergence of an OIIA-LPD merits close attention in patients receiving immune checkpoint inhibitors.
引用
收藏
页数:5
相关论文
共 50 条
  • [1] Progressive multifocal leukoencephalopathy associated with a lymphoproliferative disorder treated with pembrolizumab
    Holmes, Alex
    Wellings, Tom
    Walsh, Oliver
    Rowlings, Philip
    JOURNAL OF NEUROVIROLOGY, 2020, 26 (06) : 961 - 963
  • [2] Progressive multifocal leukoencephalopathy associated with a lymphoproliferative disorder treated with pembrolizumab
    Alex Holmes
    Tom Wellings
    Oliver Walsh
    Philip Rowlings
    Journal of NeuroVirology, 2020, 26 : 961 - 963
  • [3] Intracerebral lymphoproliferative disorder in an MS patient treated with fingolimod
    de Jong, Brigit A.
    van Kempen, Zoe L. E.
    Wattjes, Mike P.
    Smit, Patrick M.
    Peferoen, Laura
    Berry, Daniella
    Chamuleau, Martine E. D.
    de Jong, Daphne
    NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2018, 5 (05):
  • [4] Pembrolizumab for the treatment of esophageal cancer
    Yamamoto, Shun
    Kato, Ken
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2020, 20 (10) : 1143 - 1149
  • [5] Pembrolizumab for the treatment of advanced esophageal cancer
    Harada, Kentaro
    Yamamoto, Shun
    Kato, Ken
    FUTURE ONCOLOGY, 2022, 18 (18) : 2311 - 2319
  • [6] Reversible Methotrexate-Associated Lymphoproliferative Disorder Resembling Advanced Gastric Cancer in a Patient With Rheumatoid Arthritis
    Satoh, Ken
    Yoshida, Naomi
    Imaizumi, Kazuomi
    Yajima, Mioko
    Wakui, Hideki
    Sawada, Ken-ichi
    Komatsuda, Atsushi
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2009, 338 (04) : 334 - 335
  • [7] A case of esophageal cancer complicated with methotrexate-related lymphoproliferative disorder
    Maruyama, Tsunehiko
    Sako, Akihiro
    Ueda, Kazumitsu
    Suzuki, Shuji
    CLINICAL JOURNAL OF GASTROENTEROLOGY, 2020, 13 (04) : 483 - 487
  • [8] Cutaneous EBV-associated lymphoproliferative disorder in a dermatomyositis treated with immunosuppressive agents
    Steff, M.
    Le Corre, Y.
    Penisson-Besnier, I.
    Michalak, S.
    Drossard, G.
    Lebrun-Vignes, B.
    Le Clec'h, C.
    REVUE DE MEDECINE INTERNE, 2009, 30 (08): : 720 - 723
  • [9] Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab
    Lau, K. H. Vincent
    Kumar, Aditya
    Yang, Irene Hwa
    Nowak, Richard J.
    MUSCLE & NERVE, 2016, 54 (01) : 157 - 161
  • [10] Bullous Pemphigoid in a Patient Treated with Pembrolizumab
    Hara, Kanako
    Yamasaki, Kei
    Yamada, Shigenori
    Yatera, Kazuhiro
    INTERNAL MEDICINE, 2020, 59 (01) : 139 - 140